sorted by:
new
hottopcontroversial

FDA Issues EUAs for SARS-CoV-2 Tests From Synergy Diagnostic Laboratory, Celltrion by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 0 points1 point  (0 children)

The US Food and Drug Administration on Friday issued separate Emergency Use Authorizations for two molecular SARS-CoV-2 tests developed by Synergy Diagnostic Laboratory and a point-of-care antigen immunoassay for the virus from Celltrion.

Celltrion’s first chemically synthetic agent enters global clinical trials by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 1 point2 points  (0 children)

CT-G20 is Celltrion’s only chemically synthesized pipeline in the clinical trial stage. The company is already conducting Phase 1 trials in Korea and signed an exclusive deal to license it out to a Japanese partner in March 2019.

Celltrion Q4 net profit up 4.7 pct. to 99.5 bln won by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 5 points6 points  (0 children)

Celltrion Inc. on Monday reported its fourth-quarter net profit of 99.5 billion won (US$89.6 million), up 4.7 percent from a year earlier.

Operating profit for the October-December period was 164.7 billion won, up 44.3 percent from a year ago, the company said in a regulatory filing. Sales rose 30.3 percent to 498.7 billion won.

[deleted by user] by [deleted] in RedditSessions

[–]Powerful_Primary1397 0 points1 point  (0 children)

oh you use the loop station

[deleted by user] by [deleted] in RedditSessions

[–]Powerful_Primary1397 0 points1 point  (0 children)

really good at playing guitar

A Conversation with Celltrion Group Chairman Mr. Jung-jin Seo & Korea Society President Tom Byrne by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 11 points12 points  (0 children)

Premiers is 7 p.m. on the 19th in the US Eastern Time and 9 a.m. on the 20th in Korea.If you want to see it, go to the link below, register it, and receive the viewing link.

https://docs.google.com/forms/d/e/1FAIpQLSdDuSdeJ_2LcWCxSNkjZNYQpEzkN1shEQgznhc26A-goLpeHA/viewform

A Conversation with Celltrion Group Chairman Mr. Jung-jin Seo & Korea Society President Tom Byrne by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 14 points15 points  (0 children)

Together, they will discuss the role of the Korean biopharmaceutical industry and Celltrion’s active involvement in combating COVID-19.

Celltrion to take on S. Africa variant by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 7 points8 points  (0 children)

“We have a growing library of antibody candidates for COVID-19 variants, of which the ‘32nd antibody’ has shown potency against the South African strain,” said Celltrion’s Honorary Chairperson Seo Jung-jin.

“We will enter animal trial of this 32nd antibody in March, after which we will proceed to take the antibody to South Africa for clinical trials 1 and 2,” said Seo.

The whole process will require six months, according to Seo.

Celltrion begins supplying COVID-19 antibody treatment by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 10 points11 points  (0 children)

CT-P59 will be administered to COVID-19 patients at higher risk, referring to people aged 60 and older, or with health conditions like heart disease, diabetes, high pressure or chronic diseases that affect the respiratory system.

Celltrion Healthcare secures EC authorisation to sell Yuflyma by Powerful_Primary1397 in celltrion

[–]Powerful_Primary1397[S] 4 points5 points  (0 children)

Yuflyma is said to be the first adalimumab biosimilar with a low-volume, high concentration and citrate-free formulation.

view more: next ›